Neurochemical and neuropharmacological aspects of depression.
D000224:Addison Disease / Q000150:complications; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000662:Amphetamines / Q000627:therapeutic use; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003480:Cushing Syndrome / Q000150:complications; D000242:Cyclic AMP / Q000378:metabolism; D003863:Depression / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D004565:Electroconvulsive Therapy; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008781:Methyltyrosines / Q000009:adverse effects; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D012110:Reserpine / Q000009:adverse effects; D014364:Tryptophan / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000662:Amphetamines; D000929:Antidepressive Agents, Tricyclic; D008781:Methyltyrosines; D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents; D012110:Reserpine; D014364:Tryptophan; D008094:Lithium; D000242:Cyclic AMP